{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:59:46Z","timestamp":1772233186030,"version":"3.50.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Learning Objectives<\/jats:title>\n                    <jats:p>After completing this course, the reader will be able to: Discuss the role of bisphosphonate therapy in the management of metastatic bone disease.Describe the differences between individual bisphosphonates with regard to safety and route of administration.List the reasons for including elderly patients in clinical trials of bisphosphonates for the management of metastatic bone disease.<\/jats:p>\n                    <jats:p>CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.12-1-62","type":"journal-article","created":{"date-parts":[[2007,1,16]],"date-time":"2007-01-16T19:25:32Z","timestamp":1168975532000},"page":"62-71","source":"Crossref","is-referenced-by-count":17,"title":["The Use of Bisphosphonates in Elderly Cancer Patients"],"prefix":"10.1093","volume":"12","author":[{"given":"Cesare","family":"Gridelli","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,1,1]]},"reference":[{"key":"2021122208295997800_R1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0889-8588(05)70275-6","article-title":"Aging and cancer in America. Demographic and epidemiologic perspectives","volume":"14","author":"Yancik","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122208295997800_R2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122208295997800_R3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"issue":"suppl 4","key":"2021122208295997800_R4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: Clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"The Oncologist"},{"key":"2021122208295997800_R5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1634\/theoncologist.11-3-227","article-title":"Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer","volume":"11","author":"Clemons","year":"2006","journal-title":"The Oncologist"},{"key":"2021122208295997800_R6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"2021122208295997800_R8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: A randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"key":"2021122208295997800_R9","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [in French]","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"2021122208295997800_R10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease","volume":"12","author":"Jagdev","year":"2001","journal-title":"Ann Oncol"},{"key":"2021122208295997800_R11","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122208295997800_R14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myleoma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R15","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multi-center, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R16","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2021122208295997800_R17","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2021122208295997800_R18","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122208295997800_R19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122208295997800_R20","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R21","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R22","first-page":"428a","article-title":"The use of zoledronic acid in the treatment of painful bone metastases from prostate cancer","volume":"22","author":"Fulfaro","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208295997800_R23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"The Oncologist"},{"key":"2021122208295997800_R24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: A randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"2021122208295997800_R25","first-page":"46a","article-title":"Risk reductions in metastatic breast cancer: Multivariate Poisson regression analyses of oral and i.v. ibandronate","volume":"22","author":"Body","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208295997800_R26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"issue":"suppl 1","key":"2021122208295997800_R27","first-page":"S91","article-title":"Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: A methodological comparison","volume":"34","author":"Tripathy","year":"2004","journal-title":"Bone"},{"key":"2021122208295997800_R28","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122208295997800_R29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"2021122208295997800_R30","first-page":"69a","article-title":"Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Comparative bone turnover marker and safety data","volume":"38","author":"Body","year":"2006","journal-title":"Bone"},{"issue":"suppl 1","key":"2021122208295997800_R31","doi-asserted-by":"crossref","first-page":"67a","DOI":"10.1016\/j.bone.2006.01.008","article-title":"Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: The NCRI ZICE trial","volume":"38","author":"Barrett-Lee","year":"2006","journal-title":"Bone"},{"issue":"suppl 1","key":"2021122208295997800_R32","doi-asserted-by":"crossref","first-page":"82a","DOI":"10.1016\/j.bone.2006.01.047","article-title":"Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: The SWOG trial","volume":"38","author":"Rivkin","year":"2006","journal-title":"Bone"},{"key":"2021122208295997800_R33","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122208295997800_R34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"suppl 5","key":"2021122208295997800_R35","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S1359-6349(03)90923-2","article-title":"High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer","volume":"1","author":"Heidenreich","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122208295997800_R36","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: A pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021122208295997800_R37","first-page":"CD003474","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Co-chrane Database Syst Rev"},{"key":"2021122208295997800_R38","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122208295997800_R39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ndt\/15.3.301","article-title":"Multiple myeloma and renal failure","volume":"15","author":"Goldschmidt","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"2021122208295997800_R40","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0022-5347(01)62228-6","article-title":"Hydronephrosis as a prognostic indicator in bladder cancer patients","volume":"160","author":"Haleblian","year":"1998","journal-title":"J Urol"},{"key":"2021122208295997800_R41","first-page":"521","article-title":"Renal toxicities of chemotherapy","volume":"19","author":"Patterson","year":"1992","journal-title":"Semin Oncol"},{"key":"2021122208295997800_R42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcaemia of malignancy","volume":"21","author":"Zojer","year":"1999","journal-title":"Drug Saf"},{"key":"2021122208295997800_R43","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00002018-200326090-00005","article-title":"Extended safety profile of oral clodronate after long-term use in primary breast cancer patients","volume":"26","author":"Atula","year":"2003","journal-title":"Drug Saf"},{"key":"2021122208295997800_R44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000080996","article-title":"Safety of long-term administration of bisphosphonates in elderly cancer patients","volume":"67","author":"Tralongo","year":"2004","journal-title":"Oncology"},{"key":"2021122208295997800_R45","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2021122208295997800_R46","doi-asserted-by":"crossref","first-page":"87a","DOI":"10.1016\/j.bone.2006.01.158","article-title":"Comparison of renal impairment in multiple myeloma patients treated with zoledronic acid or ibandronate: A retrospective medical records review","volume":"38","author":"Antr\u00e1s","year":"2006","journal-title":"Bone"},{"key":"2021122208295997800_R47","volume-title":"Zometa\u00ae (zoledronic acid). US summary of product characteristics","author":"Novartis Pharmaceuticals Corporation","year":"2004"},{"key":"2021122208295997800_R48","volume-title":"Zometa\u00ae (zoledronic acid). EU summary of product characteristics","author":"Novartis International AG","year":"2005,"},{"key":"2021122208295997800_R49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2354.2005.00641.x","article-title":"Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results","volume":"15","author":"Body","year":"2006","journal-title":"Eur J Cancer Care"},{"key":"2021122208295997800_R50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","article-title":"Long-term safety of intravenous ibandronate for up to 4 years in metastatic breast cancer: An open-label trial","volume":"26","author":"Pecherstorfer","year":"2006","journal-title":"Clin Drug Invest"},{"issue":"suppl 1","key":"2021122208295997800_R51","first-page":"S50","article-title":"Renal safety of loading dose ibandronate in urologic patients with compensated renal insufficiency","volume":"31","author":"Heidenreich","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"2021122208295997800_R52","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R53","first-page":"21a","article-title":"Ibandronate in the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure","volume":"13","author":"Henrich","year":"2005","journal-title":"Support Care Cancer"},{"key":"2021122208295997800_R54","article-title":"Renal safety of ibandronate in elderly myeloma patients with pre-existing renal deterioration","volume-title":"Paper presented at: Sixth Conference of the International Society for Geriatric Oncology","author":"Henrich","year":"2005"},{"issue":"suppl 1","key":"2021122208295997800_R55","doi-asserted-by":"crossref","first-page":"68a","DOI":"10.1016\/j.bone.2006.01.012","article-title":"Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: Evidence from comparative phase II\/III trials","volume":"38","author":"Bergstr\u00f6m","year":"2006","journal-title":"Bone"},{"key":"2021122208295997800_R56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"2021122208295997800_R57","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R58","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R59","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1995.13.9.2427","article-title":"Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study","volume":"13","author":"Robertson","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122208295997800_R60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00044011-200626010-00006","article-title":"Safety of oral ibandronate in the treatment of bone metastases from breast cancer: Long-term follow-up experience","volume":"26","author":"McLachlan S-A, Cameron","year":"2006","journal-title":"Clin Drug Invest"},{"key":"2021122208295997800_R61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"key":"2021122208295997800_R62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0093-7754(01)90229-5","article-title":"Bone metastases: Approaches to management","volume":"28","author":"Janjan","year":"2001","journal-title":"Semin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-1-62","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-1-62","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/1\/62\/41834858\/oncolo_12_1_62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/1\/62\/41834858\/oncolo_12_1_62.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T09:20:15Z","timestamp":1640164815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/1\/62\/6410014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,1,1]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-1-62","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1066780.519680","asserted-by":"object"}]},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,1,1]]},"published":{"date-parts":[[2007,1,1]]}}}